Prometheus Biosciences, Inc. (RXDX) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है San Diego, CA, United States. वर्तमान CEO हैं Mark C. McKenna.
RXDX के पास है IPO तिथि 2021-03-12, 97 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $9.56B.
Prometheus Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and companion diagnostics for inflammatory bowel diseases (IBD). The company's lead candidate, PRA023, is a humanized monoclonal antibody currently in Phase IIa clinical trials for ulcerative colitis, Crohn's disease, and systemic sclerosis-associated interstitial lung disease. Prometheus maintains a robust pipeline including multiple therapeutic programs targeting different disease mechanisms in IBD and immune-mediated conditions, supported by strategic partnerships with leading pharmaceutical companies including Takeda, Dr. Falk Pharma, and Millennium Pharmaceuticals. Headquartered in San Diego, California, the company was incorporated in 2016 and formerly operated under the name Precision IBD, Inc. before rebranding to Prometheus Biosciences in October 2019.
